Go Pro
NYSE:RFL

Rafael Q3 2025 Earnings Report

Rafael logo
$2.78 -0.37 (-11.71%)
Closing price 03:59 PM Eastern
Extended Trading
$2.70 -0.08 (-2.73%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, June 11, 2025
Conference Call Time
7:00AM ET

Rafael Earnings Headlines

Three companies about to leapfrog Nvidia [And transform the entire industry]
Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted mobile computing years before the iPhone - has identified three companies he calls the 'Trillion Dollar Triangle.' One of them went public just weeks ago. Demand for its technology is already outpacing supply, with major AI players among its biggest customers. Gilder says this kind of supply crunch is the tell that a new technology is transitioning from possibility to inevitability.tc pixel
Rafael B Stock Price History
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile